Remote patient monitoring (RPM)
Remote patient monitoring (RPM) presents a major opportunity for China's wearable medical device market by leveraging 5G infrastructure, aging demographics, and policy-backed digital health reforms to enable scalable chronic care outside hospitals, reducing readmissions and easing resource strains. Under the "Internet Plus Healthcare" framework and 14th Five-Year Plan, NMPA-approved wearables like Huawei Watch D2 integrate with telemedicine platforms for continuous vitals transmission BP, ECG, SpO2 to cloud dashboards, supporting follow-ups for hypertension and diabetes without offline prerequisites for stable cases.
By late 2024, over 4 million 5G base stations enabled low-latency RPM streaming, with pilots in smart wards using patches for ICU step-downs and home monitoring of 216 million elderly, aligning with the national target for 97% community-based senior care. For example, the Huawei Blood Pressure Health Study (2022–2024) across 31 provinces engaged 75,918 users, where 73.8% tracked BP via wearables, triggering 78% compliance on alerts and linking data to physician reviews, demonstrating RPM's role in averting escalations.
Internet hospitals, by June 2023, the number of internet hospitals had reached more than 3,000, and 364 million of China’s 1.079 billion internet users were using online medical services, with physicians needing 3+ years' experience and patient consent, fostering ecosystems where Xiaomi and Alibaba platforms aggregate wearable feeds for predictive analytics. Amid post-COVID hospital-at-home surges, RPM wearables address 300 million cardiovascular cases by enabling real-time interventions, positioning China as a leader in connected care.
Integration with AI and predictive analytics
Integration with AI and predictive analytics offers a significant opportunity for the China wearable medical device market by enhancing real-time diagnostics, personalized health management, and early disease detection, aligning with China’s strong policy backing and technological infrastructure. AI-powered wearables leverage advances in machine learning to interpret vast physiological data streams heart rate, ECG, blood pressure, glucose and generate predictive insights that support preventive care and early interventions, improving outcomes for chronic diseases like cardiovascular conditions and diabetes.
For example, tech conglomerates such as Tencent, Alibaba, and Huawei are deeply investing in AI-enabled wearable solutions; the partnership between Zhongshan Hospital, Huawei, and iFlytek developed multimodal AI tools integrating voice assistants and clinical decision support, while Tsinghua University’s AI system achieved over 93% diagnostic accuracy across 300+ diseases, illustrating how AI-driven wearables contribute to clinical decision-making and workflow efficiency.
The rise of 5G connectivity coupled with AI facilitates low-latency data transmission from wearables to cloud platforms, enabling continuous remote patient monitoring and predictive analytics within telehealth ecosystems, a synergy emphasized in government strategies like “Made in China 2025” and healthcare AI reform programs driving scenario-based adoption.
In 2025, WORK Medical Technology partnered with Ruijin Hospital to boost next-generation AI-enabled smart clinical ecosystems, while Johnson & Johnson and Qure.ai collaborated on AI for early lung cancer detection, underscoring multinational interest in AI wearables market. These integrations support proactive health management by predicting risks before clinical symptoms onset, facilitating tailored treatment regimens, and optimizing resource allocation, positioning China as a leader in AI-powered wearable medical technologies.
Expansion into fitness / preventive healthcare
Expansion into fitness and preventive healthcare represents a key opportunity for China's wearable medical device market by bridging consumer wellness gadgets with clinical-grade monitoring, capitalizing on rising health literacy, lifestyle disease burdens, and policy support for proactive care amid urbanization and sedentary trends. Fitness trackers and smartwatches dominate as entry points, tracking steps, heart rate, sleep, and energy expenditure to empower users toward sustained activity and early anomaly detection, aligning with the "Healthy China" initiative in the 14th Five-Year Plan that promotes personal health oversight.
Approximately 270 million Chinese suffer from hypertension, with only 13.8% achieving control per WHO data, driving demand for devices that enable daily vitals logging and behavior nudges to avert escalations. Athletes and fitness enthusiasts increasingly adopt wearables for performance optimization, while urban millennials integrate them into routines for preventive screening of risks like prediabetes or irregular rhythms. In May 2025, LifeQ partnered with BlueZone to launch a biometrics platform in mainland China, blending wearable data with AI insights for digital health apps focused on home-based wellness and remote coaching.
Market Factor Analysis
Regulatory Environment & Compliance
Regulatory Authority
The primary regulator is the National Medical Products Administration (NMPA).
There is also a technical evaluation body, the Chinese Medical Device Evaluation (CMDE), which plays a role in assessing registration dossiers.
Device Classification System
China classifies medical devices into three classes: Class I, II, and III, based on risk.
As Per the Provisions for Medical Device Registration and Filing (effective Oct 1, 2021), Class I devices are managed via filing, while Classes II and III require registration.
Recently (effective Sep 1, 2024), the NMPA updated its classification process for newly developed devices to better standardize classification submissions.
For wearable medical devices, many fall under Class II, due to their moderate risk; fewer are Class III.
Regulatory Requirements for Registration / Filing
Documentation: Applicants must submit a technical dossier (Product Technical Requirements, PTR) that includes functional/safety indicators, test methods, etc.
Quality Management System (QMS): The applicant/filer must implement a QMS appropriate to the product; for many devices, ISO 13485 is relevant, and Chinese GMP inspections may apply.
Labeling and Instructions: Instructions for use (IFU) and labels must be provided; submissions must be in Chinese (Simplified), and translated versions of foreign-language documents are required.
Standards: Devices must conform to applicable Chinese mandatory standards. If a device does not fully map to a standard (e.g., novel wearable), the applicant must provide a justification statement and supporting documentation.
Safety / Risk Management: Risk management principles must be embedded in R&D; every foreseeable risk should be managed, and benefits must outweigh risks under typical use.
Clinical Trials and Testing
Many Class II and Class III devices require type-testing in NMPA-designated labs in China.
For higher-risk devices (especially Class III), clinical trials may be required.
Importantly, trial requirements may demand in-country clinical evaluation or local data, increasing cost and complexity.
Registration Validity and Renewal
Registration certificates for Class II and Class III devices are valid for 5 years.
A renewal application should be submitted at least 6 months before expiration.
If there are significant changes in design, materials, manufacturing, or use, a “change-registration” is required; lesser changes may only need to be filed.
Priority & Emergency Procedures
Priority Registration: Some devices (e.g., those for rare diseases, or with significant clinical advantages) may be eligible for a priority registration path.
